Skip to content
Screener

ImmunityBio, Inc. IBRX Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$44.2MBeat by $1.1M
EPS-$0.09Miss by $0.01
Revenue estimate$43.1M
EPS estimate-$0.08

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$59.2M
EPS estimate-$0.08

Financials

Q1 2026

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$7.92B+208%
Enterprise value$8.16B+187%
P/S56.2×-26.1×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Current ratio6.7×+4.4×

Segments

By segment

See full
Reportable Segment$44.2M+168%

FAQ

When did ImmunityBio, Inc. report Q1 2026 earnings?
ImmunityBio, Inc. (IBRX) reported Q1 2026 earnings on May 7, 2026 before market open.
What were ImmunityBio, Inc.'s Q1 2026 revenue and EPS?
ImmunityBio, Inc. reported revenue of $44.2M and eps of $-0.09 for Q1 2026.
Did ImmunityBio, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $43.1M by $1.1M. EPS missed the consensus estimate of $-0.08 by $0.01.
How did ImmunityBio, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 167.6% from $16.5M a year earlier and eps grew 40.0% from $-0.15.
Where can I find ImmunityBio, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001326110-26-000057) and the 10-Q periodic report (0001326110-26-000059) directly on SEC EDGAR. The filing index links above go to sec.gov.